approval
saveVENCLEXTA (VENETOCLAX) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026 · 159d ago
- phase 3 initiationInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)Apr 29, 2026 · 160d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalFeb 19, 2026 · 229d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalJun 15, 2022 · 1574d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 22, 2021 · 1810d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 4, 2021 · 1828d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalNov 19, 2020 · 2147d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 16, 2020 · 2181d ago
same company · ±60 days · 6
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalApr 13, 2016
- approvallinaclotide: LINZESS (LINACLOTIDE) — FDA approvalApr 6, 2016
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMar 21, 2016
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 6, 2016
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 6, 2016
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 12, 2016
🐶 often sniffed alongside
top 7- drugVENCLEXTA82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that